A 64-year-old Caucasian male presented for a comprehensive eye exam with chief complaint of mild blur at distance and near with his progressive addition lenses as well as a peeling anti-reflective coating.
Seems innocent, right? Let’s take a deeper look as the case unfolds.
The patient’s medical history was significant for hypertension, high cholesterol, and generalized anxiety for which he was taking amlodipine and simvastatin (Zocor, Merck), while alprazolam (Xanax, Pfizer) was administered as needed.
Remarkable surgical history was pertinent for a hernia repair. He reported an allergy to aspirin, resulting in cramps.
Related: The case of the scarred retina
Clinical findings and management
His blood pressure was measured as 102/70 mm Hg at 2:31 p.m. with a height of 5’10” and weight of 165 pounds, resulting in a normal BMI of 23.7. He reported regular exercise and did not smoke.
Color vision was normal in each eye as well as stereopsis along with all other entrance testing. Of note, there was a small hyperopic and astigmatic shift in each eye, resulting in best corrected vision of 20/20.
Intraocular pressure and anterior segment were unremarkable other than mild cortical cataracts. The posterior segment was also unremarkable, except for a 0.25 disc diameter-sized yellow lesion that happened to be inferotemporal parafoveal in each eye (Figures 1 and 2).
Noting this finding and what appeared to be soft confluent drusen and pigment mottling OD, the patient was advised to return for dark adaptation and ocular coherence tomography (OCT) OU.
Dark adaptation (AdaptDx MacuLogix) testing was reliable (<30 percent fixation errors) but delayed in the right eye with a rod intercept of 11.41 minutes and normal in the left eye at 3.46 minutes.
Macular OCT revealed a sub-retinal pigment epithelium (RPE) elevation in each eye as well as classic subtle deflections evident of drusen and vitreomacular adhesions (Figures 3 and 4).
The patient then underwent Macula Risk (ArcticDx) genetic testing via cheek swab.
Results noted nine out of 15 genetic markers as high risk, classifying the patient as MR4 with a 6 percent, 16 percent, and 32 percent likelihood of developing advanced age-related macular degeneration (AMD) in two, five, and 10 years, respectively (Figure 6).
The patient was asked to return to discuss the results, which also specified which supplement he should be taking to reduce his risk of progressing to advanced AMD. There was no family history of AMD, which can increase the odds of a patient having AMD by 27.8 times with an affected parent or 12 times with an affected sibling.1
1. Shahid H, Khan JC, Cipriani V, et al. Age-related macular degeneration: the importance of family history as a risk factor. Br J Ophthalmol 2012;96(3):427-31.
2. Sun H, Tsunenari T, Yau KW, et al. The vitelliform macular dystrophy protein defines a new family of chloride channels. Proc Natl Acad Sci U S A 2002;99(6):4008-13.
3. Spaide RF, Noble K, Morgan A, et al. Vitelliform macular dystrophy. Ophthalmology 2006;113(8):1392-400.
4. Yu Y, Reynolds R, Rosner B, Daly MJ, Seddon JM. Prospective assessment of genetic effects on progression to different stages of age-related macular degeneration using multistate Markov models. Invest Ophthalmol Vis Sci. 2012;53(3):1548–1556.